BCWORLD PHARM. Co. Ltd (200780) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of BCWORLD PHARM. Co. Ltd stock KRW 4,895, price KRW 2,845, upside +72.1%, quality 30 out of 100. Rating: strongly undervalued. Calculated from audited financials with 11 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 2,760 KRW – 17,121 KRW · fair‑value band 2,000 KRW – 7,790 KRW · the 2,845 KRW price screens below the 4,895 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow BCWORLD PHARM. Co. in your weekly email
Every Wednesday you see whether BCWORLD PHARM. Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BCWORLD PHARM. Co., Ltd. operates as a pharmaceutical company in South Korea.
Show moreShow less
The company provides products in various therapeutic areas comprising musculoskeletal system, digestive system, circulatory machine, central nervous system, adrenocorticosteroids, narcotic analgesics, erectile dysfunction treatment, wellbeing injection, diuretic, antitussive expectorant, vaginitis treatment, anti-tuberculosis drugs, anti-emetic, antiviral drugs, antibiotic, anti-malignant tumor drugs, antifungal agent, antihistamines, antidote, and antipyretic/analgesic/anti-inflammatory.
BCWORLD PHARM. Co., Ltd. was founded in 1980 and is headquartered in Seongnam-si, South Korea.
Stock analysis
BCWORLD PHARM. Co. Ltd (200780) currently trades at 2,845 KRW, while our model-based Fair Value estimate is 4,895 KRW, implying the stock looks roughly 42% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 7,197 KRW per share, and 9 of the 11 models we run sit above the 2,845 KRW price.
Bear case: the Earnings-Based group reads lowest at 1,083 KRW, and 2 of the 11 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 2,000 KRW (bear) to 7,790 KRW (bull), the price of 2,845 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
BCWORLD PHARM. Co. Ltd reported revenue of 75.8B KRW in FY2025 versus 62.1B KRW in FY2021, a compound +5.1%/yr. Reported net income was −4.9B KRW in FY2025.
Key figures
Market cap 29.1B KRW (≈ $21.5M) Micro · P/S ratio 0.35 · EPS (TTM) −283.48 KRW · Dividend yield 3.5% · Net margin −3.6% · Return on equity −1.8% · Return on assets (EBIT) 1.1% (5-year average) · Operating margin 0.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).
What moves the price
The share trades about 52% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at 72%, 200780 screens cheaper than that median.
Fair Value models
Bear2,000 KRWFair Value 4,895 KRWBull7,790 KRW
Price 2,845 KRW · Upside +72.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF4,713 KRW7,197 KRW10,692 KRW80
Growth DCF4,842 KRW7,108 KRW10,143 KRW78
5Y EBITDA Exit6,902 KRW11,639 KRW17,006 KRW74
All 11 models by family
DCF Models
FCF DCF4,713 KRW7,197 KRW10,692 KRW80
5Y Revenue Exit2,294 KRW3,333 KRW4,563 KRW73
5Y EBITDA Exit6,902 KRW11,639 KRW17,006 KRW74
10Y Revenue Exit3,115 KRW4,223 KRW5,527 KRW68
10Y EBITDA Exit6,013 KRW9,784 KRW14,555 KRW68
Earnings-Based
EPV824.17 KRW1,083 KRW1,308 KRW74
Multiples
EV/EBITDA2,353 KRW5,759 KRW9,165 KRW63
Asset-Based
NCAV (Graham)3,363 KRW4,506 KRW6,725 KRW54
Growth DCF
Growth DCF4,842 KRW7,108 KRW10,143 KRW78
Rev-Margin DCF2,294 KRW3,425 KRW4,697 KRW73
Economic Profit
ROIC Compounder824.17 KRW1,083 KRW1,308 KRW72
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.43/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.9%
Start year 2020 (pandemic). Over 10 years: +6.2% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
5.8% (2020) → 2.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+32.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +29.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score30 · Bottom 25%
Fair Value upside+72.1% · Top 25%
Profitability
Return on assets−2.8% · Bottom 25%
Net margin (12 months)−3.6% · Bottom 25%
Operating margin (12 months)0.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)2.5% · Below median
Dividend yield (12 months)3.5% · Top 25%
Balance sheet
Debt / equity0.20× · Above median
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
P/B0.41× · Cheapest 25%
P/S (12 months)0.36× · Cheapest 25%
Price / free cash flow (fiscal year)18.5× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is BCWORLD PHARM. Co. Ltd (200780) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 4,895 KRW versus a price of 2,845 KRW, about +72% upside (undervalued).
What is the fair value of 200780?
Our model-based fair value for BCWORLD PHARM. Co. Ltd is 4,895 KRW (as of Nov 3, 2026), built from audited fundamentals. The current price: 2,845 KRW.
What is the quality score of 200780?
BCWORLD PHARM. Co. Ltd has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BCWORLD PHARM. Co. Ltd (200780)?
Our model-based price target is the fair value of 4,895 KRW (as of Nov 3, 2026) from 11 valuation models. Cautious scenario 2,000 KRW, optimistic scenario 7,790 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the BCWORLD PHARM. Co. Ltd stock forecast for 2026?
Our models put fair value at 4,895 KRW, about +72% upside versus a price of 2,845 KRW (undervalued). Cautious scenario 2,000 KRW, optimistic scenario 7,790 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of BCWORLD PHARM. Co. Ltd (200780)?
BCWORLD PHARM. Co. Ltd reported trailing-twelve-month revenue of about 80.3B KRW (latest available figure, as of Nov 3, 2026).
Does BCWORLD PHARM. Co. Ltd pay a dividend?
BCWORLD PHARM. Co. Ltd currently shows a dividend yield of 3.51% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of BCWORLD PHARM. Co. Ltd (200780) and when is the ex-dividend date?
BCWORLD PHARM. Co. Ltd pays a dividend of 100.00 KRW per share a year, a dividend yield of 3.5%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since 2016. Free cash flow covers the dividend 1.54 times. Our assessment: Cash covered. The dividend is fully funded by free cash flow. The payout ratio on earnings is not available for this company.
What growth is priced into BCWORLD PHARM. Co. Ltd (200780)?
For today's price to be fair in a discounted-cash-flow model, BCWORLD PHARM. Co. Ltd would have to grow free cash flow by +32.1 % per year for five years (discount rate 9.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.9 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of 200780 use?
Our models discount BCWORLD PHARM. Co. Ltd at 9.4 %: a base by market capitalisation (nano), damped by beta 0.69, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BCWORLD PHARM. Co. Ltd that is +32.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.4 %) and the same formula as our fair value.
How much growth has BCWORLD PHARM. Co. Ltd (200780) delivered so far?
Over the past 5 years revenue at BCWORLD PHARM. Co. Ltd grew +5.9 % a year. The price currently implies free-cash-flow growth of +32.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BCWORLD PHARM. Co. Ltd (200780) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into BCWORLD PHARM. Co. Ltd (+32.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BCWORLD PHARM. Co. Ltd (200780)?
The free-cash-flow yield on the price is 5.40 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow BCWORLD PHARM. Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BCWORLD PHARM. Co. Ltd (200780)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BCWORLD PHARM. Co. Ltd it is 4,895 KRW per share (as of Nov 3, 2026), against a price of 2,845 KRW. It is the blended result of 11 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is BCWORLD PHARM. Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 200780 trades below its calculated fair value: price 2,845 KRW, fair value 4,895 KRW, a gap of about +72% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 200780?
No. The price is what the market pays today (2,845 KRW); the fair value is what the company's own numbers justify (4,895 KRW). For BCWORLD PHARM. Co. Ltd the two are 2,050 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is BCWORLD PHARM. Co. Ltd worth?
The market values BCWORLD PHARM. Co. Ltd at about 29.1B KRW (market capitalisation, as of Nov 3, 2026). Per share that is 2,845 KRW; our models calculate a fair value of 4,895 KRW per share.
What do the bullish and bearish scenarios say about 200780?
Our models span a range for BCWORLD PHARM. Co. Ltd: cautious scenario 2,000 KRW, base 4,895 KRW, optimistic 7,790 KRW per share (as of Nov 3, 2026, price 2,845 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BCWORLD PHARM. Co. Ltd (200780)?
Balance-sheet figures for BCWORLD PHARM. Co. Ltd (as of Nov 3, 2026): return on equity −1.8%, debt of 0.20 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is 200780 from its 52-week high?
BCWORLD PHARM. Co. Ltd trades at 2,845 KRW, about 52% below its 52-week high of 5,870 KRW and 3% above the low of 2,760 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 4,895 KRW is for.
Which stocks are comparable to BCWORLD PHARM. Co. Ltd?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BCWORLD PHARM. Co. Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price 2,845 KRW, calculated fair value 4,895 KRW (+72%), Quality Score 30/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 200780 calculated?
We run BCWORLD PHARM. Co. Ltd through 11 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of 4,895 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. BCWORLD PHARM. Co. Ltd currently trades 42% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BCWORLD PHARM. Co. Ltd (200780)?
The closing price on Nov 9, 2026 was 2,845 KRW. Our model-based fair value is 4,895 KRW, about +72% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BCWORLD PHARM. Co. Ltd right now?
The large discount to fair value meets weak quality (30/100). That raises the risk this is a value trap rather than a bargain. The model range is unusually wide (2,000 KRW to 7,790 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Key figures of BCWORLD PHARM. Co. Ltd
How large is the market capitalisation of BCWORLD PHARM. Co. Ltd (200780)?
The market capitalisation of BCWORLD PHARM. Co. Ltd is 29.1B KRW (≈ $21.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BCWORLD PHARM. Co. Ltd (200780)?
The price-to-sales ratio of BCWORLD PHARM. Co. Ltd is 0.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BCWORLD PHARM. Co. Ltd (200780)?
Earnings per share at BCWORLD PHARM. Co. Ltd are −283.48 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of BCWORLD PHARM. Co. Ltd (200780)?
The dividend yield of BCWORLD PHARM. Co. Ltd is 3.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of BCWORLD PHARM. Co. Ltd (200780)?
The net margin of BCWORLD PHARM. Co. Ltd is −3.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BCWORLD PHARM. Co. Ltd (200780)?
The return on equity (ROE) of BCWORLD PHARM. Co. Ltd is −1.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BCWORLD PHARM. Co. Ltd (200780)?
On an EBIT basis the return on assets of BCWORLD PHARM. Co. Ltd is 1.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BCWORLD PHARM. Co. Ltd (200780)?
The operating margin of BCWORLD PHARM. Co. Ltd is 0.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BCWORLD PHARM. Co. Ltd (200780)?
Revenue at BCWORLD PHARM. Co. Ltd is growing +2.5% versus a year earlier (3y avg +1.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BCWORLD PHARM. Co. Ltd (200780)?
Earnings per share at BCWORLD PHARM. Co. Ltd are growing +807% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does BCWORLD PHARM. Co. Ltd (200780) carry?
The net debt of BCWORLD PHARM. Co. Ltd is 80.4B KRW (fiscal year 2025, ≈ 51.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch BCWORLD PHARM. Co. Ltd in the live analysis
One click puts BCWORLD PHARM. Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 3, 2026